ERCP术后胰腺炎的预防策略
|
摘要
经内镜逆行性胰胆管造影术(endoscopic retrograde cholangiopancreatography,ERCP)是胆胰疾病内镜微创诊治的重要手段,但与其他内镜操作相比,ERCP术后相关的并发症最高。ERCP术后胰腺炎(post-ERCP pancreatitis,PEP)是其中最常见的并发症,严重时可能危及生命。积极的早期预防可以有效降低PEP的发生率。目前,在临床上有明确效果的措施包括术前非甾体抗炎药纳肛和预防性胰管支架置入,使用乳酸林格氏液积极的水化也是预防PEP安全有效的方法。
Endoscopic retrograde cholangiopancreatography(ERCP) is an irreplaceable measure with minimally invasive diagnosis and treatment of endoscopy for biliary and pancreatic diseases, but the related complications associated with ERCP are the highest among the endoscopic procedures. Post-ERCP pancreatitis(PEP) is one of the most common complications with life-th reatening in severe cases. Early active prevention can effectively reduce the incidence of post-ERCP pancreatitis. At present, measures including preoperative rectal non-steroidal anti-inflammatory drugs and prophylactic pancreatic stent placement, have definite effective strategy in clinic. Aggressive hydration with lactated Ringer's solution is also a safe and effective way to prevent PEP.
Endoscopic retrograde cholangiopancreatography(ERCP) is an irreplaceable measure with minimally invasive diagnosis and treatment of endoscopy for biliary and pancreatic diseases, but the related complications associated with ERCP are the highest among the endoscopic procedures. Post-ERCP pancreatitis(PEP) is one of the most common complications with life-th reatening in severe cases. Early active prevention can effectively reduce the incidence of post-ERCP pancreatitis. At present, measures including preoperative rectal non-steroidal anti-inflammatory drugs and prophylactic pancreatic stent placement, have definite effective strategy in clinic. Aggressive hydration with lactated Ringer's solution is also a safe and effective way to prevent PEP.
引文
[1]TalukdarR.ComplicationsofERCP[J].BestPractResClinGastroenterol, 2016, 30(5):793-805.
[2]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomycomplications and their management:an attempt at consensus[J].Gastrointest Endosc, 1991, 37(3):383-393.
[3]BanksPA,BollenTL,DervenisC,etal.Classificationofacutepancreatitis—2012:revisionoftheAtlantaclassificationanddefinitions by international consensus[J]. Gut, 2013, 62(1):102-111.
[4]Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications:A systematic survey of prospective studies[J].Am J Gastroenterol, 2007, 102(8):1781-1788.
[5]Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, andmortality of post-ERCP pancreatitis:a systematic review by usingrandomized, controlled trials[J]. Gastrointest Endosc, 2015, 81(1):143-149.
[6]Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis:European Society of Gastrointestinal Endoscopy(ESGE)Guideline-updated June 2014[J]. Endoscopy, 2014, 46(9):799-815.
[7]ChenJJ,WangXM,LiuXQ,etal.Riskfactorsforpost-ERCPpancreatitis:a systematic review of clinical trials with a large samplesize in the past 10 years[J]. Eur J Med Res, 2014, 19(1):26.
[8]Inamdar S, Berzin TM, Sejpal DV, et al. Pregnancy is a risk factor forpancreatitis after endoscopic retrograde cholangiopancreatography ina national cohort study[J]. Clin Gastroenterol Hepatol, 2016, 14(1):107-114.
[9]Koksal AR, Boga S, Alkim H, et al. Insulin resistance as a novel riskfactor for post-ERCP pancreatitis:A pilot study[J]. Dig Dis Sci,2016, 61(8):2397-2405.
[10]Dumonceau JM, Rigaux J, Kahaleh M, et al. Prophylaxis of post-ERCP pancreatitis:a practice survey[J]. Gastrointest Endosc, 2010,71(6):934-939.
[11]Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial ofrectal indometh acin to prevent post-ERCP pancreatitis[J]. N Engl JMed, 2012, 366(15):1414-1422.
[12]A h m a dD,L o p e zK T,E s m a d iM A,e ta l.T h ee f f e c to findometh acininthepreventionofpost-endoscopicretrogradecholangiopancreatography pancreatitis:a Meta-analysis[J]. Pancreas,2014, 43(3):338-342.
[13]AkbarA,AbuDayyehBK,BaronTH,etal.Rectalnonsteroidalant i-inf lammator ydr ugsaresu per iortopancreat icductstentsinpreventingpancreatitisafterendoscopicretrogradecholangiopancreatography:anetworkMeta-analysis[J].ClinGastroenterol Hepatol, 2013, 11(7):778-783.
[14]LuoH,ZhaoL,LeungJ,etal.Routinepre-proceduralrectalindometacin versus selective post-procedural rectal indometacin toprevent pancreatitis in patients undergoing endoscopic retrogradecholangiopancreatography:a multicentre, single-blinded, randomisedcontrolled trial[J]. Lancet, 2016, 387(10035):2293-2301.
[15]Dumonceau JM, Andriulli A, Devière J, et al. European Society ofGastrointestinal Endoscopy(ESGE)Guideline:prophylaxis of post-ERCP pancreatitis[J]. Endoscopy, 2010, 42(6):503-515.
[16]Concepción-Martín M, Gómez-Oliva C, Juanes A, et al. Somatostatinfor prevention of post-ERCP pancreatitis:a randomized, double-blind trial[J]. Endoscopy, 2014, 46(10):851-856.
[17]Bai Y, Ren X, Zhang XF, et al. Prophylactic somatostatin can reduceincidenceofpost-ERCPpancreatitis:multicenterrandomizedcontrolled trial[J]. Endoscopy, 2015, 47(5):415-420.
[18]Bai Y,Gao J,Zou DW,et al.Prophylacticoctreotid eadministrationdoesnotpreventpost-endoscopicretrogradecholangiopancreatographypancreatitis:aMeta-analysisofrandomized controlled trials[J]. Pancreas, 2008, 37(3):241-246.
[19]Zhang Y, Chen QB, Gao ZY, et al. Meta-analysis:octreotide preventspost-ERCP pancreatitis, but only at sufficient doses[J]. AlimentPharmacol Ther, 2009, 29(11):1155-1164.
[20]Omata F, Deshpande G, Tokuda Y, et al. Meta-analysis:somatostatinor its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis[J]. J Gastroenterol, 2010, 45(8):885-895.
[21]Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatinandgabexatemesylateforthepreventionofpost-endoscopicretrograde cholangiopancreatography pancreatitis:a prospective,randomized trial[J]. J Gastroenterol, 2007, 42(2):161-167.
[22]Fuji shiroH,AdachiKT,HashimotoT,etal.U l inastatins how spreventiveeffectonpost-endoscopicretrograd echolangiopancreatography pancreatitis in a multicenter prospectiverandomized study[J]. J Gastroenterol Hepatol, 2006, 21(6):1065-1069.
[23]YooYW,ChaSW,KimA,etal.Theuseofgabexatemesylateand ulinastatin for the prevention of post-endoscopic retrogradecholangiopancreatography pancreatitis[J]. Gut Liver, 2012, 6(2):256-261.
[24]Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis ofpost-ERCP pancreatitis:a Meta-analysis of randomized controlledtrials[J]. BMC Gastroenterol, 2007, 7(1):6.
[25]Seta T, Noguchi Y. Protease inhibitors for preventing complicationsassociated with ERCP:an updated Meta-analysis[J]. GastrointestEndosc, 2011, 73(4):700-706.
[26]BaiY,XuC,YangX,etal.Glyceryltrinitrateforpreventionofpancreatitis after endoscopic retrograde cholangiopancreatography:a Meta-analysis of randomized, double-blind, placebo-controlledtrials[J]. Endoscopy, 2009, 41(8):690-695.
[27]Shao LM, Chen QY, Chen MY, et al. Nitroglycerin in the preventionof post-ERCP pancreatitis:a Meta-analysis[J]. Dig Dis Sci, 2010,55(1):1-7.
[28]Chen B, Fan T, Wang C. A Meta-analysis for the e?ect of prophylacticGTNontheincidenceofpost-ERCPpancreatitisandonthesuccessful rate of cannulation of bile ducts[J]. BMC gastroenterol,2010, 10(1):85.
[29]Ding J, Jin X, Pan Y, et al. Glyceryl trinitrate for prevention of post-ERCP pancreatitis and improve the rate of cannulation:a Meta-analysis of prospective, randomized, controlled trials[J]. PLoS One,2013, 8(10):e75645.
[30]BangUC,N?jgaardC,AndersenPK,etal.Meta-analysis:Nitroglycerin for prevention of post-ERCP pancreatitis[J]. AlimentPharmacol Ther, 2009, 29(10):1078-1085.
[31]Matsushita M, Takakuwa H, Shimeno N, et al. Epinephrine sprayedonthepapillaforpreventionofpost-ERCPpancreatitis[J].JGastroenterol, 2009, 44(1):71-75.
[32]XuLH,QianJB,GuLG,etal.Preventionofpost-endoscopicretrograde cholangiopancreatography pancreatitis by epinephrinesprayed on the papilla[J]. J Gastroenterol Hepatol, 2011, 26(7):1139-1144.
[33]Sand J, Matikainen M, Nordback I. Antibiotic prophylaxis reducespost-ERCPpancreatitis[J].Gastroenterology,2000,118(4):A1062-A1062.
[34]R?ty S, Sand J, Pulkkinen M, et al. Post-ERCP pancreatitis:reductionby routine antibiotics[J]. J Gastrointest Surg, 2001, 5(4):339-345.
[35]Buxbaum J, Yan A, Yeh K, et al. Aggressive hydration with lactatedRinger’ssolutionreducespancreatitisfollowingendoscopicretrogradecholangiopancreatography[J].ClinGastroenterolHepatol, 2014, 12(2):303-307.
[36]Dimagno MJ, Wamsteker EJ, Maratt J, et al. Do larger periproceduralfluid volumes reduce the severity of post-endoscopic retrogradecholangiopancreatography pancreatitis?[J]. Pancreas, 2014, 43(4):642-647.
[37]Choi JH, Kim HJ, Lee BU, et al. Vigorous periprocedural hydrationwith lactated Ringer solution reduces the risk of pancreatitis afterretrograde cholangiopancreatography in hospitalized patients[J].Clin Gastroenterol Hepatol, 2017, 15(1):86-92.
[38]SmeetsX J,DaCD,BesselinkMG,etal.Systematicreview:periproceduralhydrationinthepreventionofpost-ERCPpancreatitis[J]. Aliment Pharmacol Ther, 2016, 44(6):541-553.
[39]ZhangZF,DuanZJ,WangLX,etal.Aggressivehydrationwith lactated Ringer solution in prevention of postendoscopic retrogradecholangiopancreatographypancreatitis:AMeta-analysisofrandomized controlled trials[J]. J Clin Gastroenterol, 2017, 51(3):e17-e26.
[40]Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotideversushydrocortisoneversusplacebointhepreventionofpost-ERCP pancreatitis:a multicenter randomized controlled trial[J].Gastrointest Endosc, 2002, 55(4):470-475.
[41]Bai Y, Gao J, Shi X, et al. Prophylactic corticosteroids do not preventpost-ERCP pancreatitis:a Meta-analysis of randomized controlledtrials[J]. Pancreatology, 2008, 8(4/5):504-509.
[42]Schwartz JJ, Lew RJ, Ahmad NA. The effect of lidocaine sprayedonthemajorduodenalpapillaonthefrequencyofpost-ERCPpancreatitis[J]. Gastrointest Endosc, 2004, 59(2):179-184.
[43]Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis:a prospective, double-blind randomized study[J].Gastrointest Endosc, 2002, 56(2):202-208.
[44]GuWJ,WeiCY,YinRX.Antioxidantsupplementationfortheprevention of post-endoscopic retrograde cholangiopancreatographypancreatitis:a Meta-analysis of randomized controlled trials[J]. NutrJ, 2013, 12(1):23.
[45]BarkayO,NivEE,BruckR,etal.Low-doseheparinforthepreventionofpost-ERCPpancreatitis:arandomizedplacebo-controlled trial[J]. Surg Endosc, 2008, 22(9):1971-1976.
[46]Sherman S, Cheng CL, Costamagna G, et al. E?cacy of recombinanth uman interleukin-10 in prevention of post-endoscopic retrogradecholangiopancreatography pancreatitis in subjects with increasedrisk[J]. Pancreas, 2009, 38(3):267-274.
[47]Dumot JA, Conwell DL, Jr ZG, et al. A randomized, double blindstudyofinterleukin10forthepreventionofERCP-inducedpancreatitis[J]. Am J Gastroenterol, 2001, 96(7):2098-2102.
[48]van Westerloo DJ, Rauws EA, Hommes D, et al. Pre-ERCP infusionof semapimod, a mitogen-activated protein kinases inhibitor, lowerspost-ERCPhyperamylasemiabutnotpancreatitisincidence[J].Gastrointest Endosc, 2008, 68(2):246-254.
[49]BaiY,GaoJ,ZhangW,etal.Meta‐analysis:allopurinolintheprevention of postendoscopic retrograde cholangiopancreatographypancreatitis[J]. Aliment Pharmacol Ther, 2008, 28(5):557-564.
[50]Li S, Cao G, Chen X, et al. Low-dose heparin in the prevention ofpost endoscopic retrograde cholangiopancreatography pancreatitis:asystematic review and Meta-analysis[J]. Eur J Gastroenterol Hepatol,2012, 24(5):477-481.
[51]KatsinelosP,KountourasJ,ParoutoglouG,etal.IntravenousN-acetylcysteinedoesnotpreventpost-ERCPpancreatitis[J].Gastrointest Endosc, 2005, 62(1):105-111.
[52]SatoD,ShibaharaT,MiyazakiK,etal.Efficacyofendoscopicnasobiliary drainage for the prevention of pancreatitis after papillaryballoon dilatation:a pilot study[J]. Pancreas, 2005, 31(1):93-97.
[53]SongLY,ZhaoQX,KongXJ,etal.EfficacyofENBDinthepreventionofpost-ERCPpancreatitisandhyperamylasemiainpatients with common bile duct stones:an analysis of 65 cases[J].World Chin J Digestol, 2010, 18(16):1724-1727.
[54]ChoudharyA,BechtoldML,ArifM,etal.Pancreaticstentsforprophylaxis against post-ERCP pancreatitis:a Meta-analysis andsystematic review[J]. Gastrointest Endosc, 2011, 73(2):275-282.
[55]ChaSW,LeungWD,LehmanGA,etal.Doesleavingamainpancreatic duct stent in place reduce the incidence of precut biliarysphincterotomy-associated pancreatitis? A randomized, prospectivestudy[J]. Gastrointest Endosc, 2013, 77(2):209-216.
[56]Arain MA, Freeman ML. Pharmacologic prophylaxis alone is notadequate to prevent post-ERCP pancreatitis[J]. Am J Gastroenterol,2014, 109(6):910-912.
[57]Ananya D, Pankaj S, Sivak MV, et al. Pancreatic-stent placementforpreventionofpost-ERCPpancreatitis:Acost-effectivenessanalysis[J]. Gastrointest Endosc, 2007, 65(7):960-968.
[58]Mazaki T, Mado K, Masuda H, et al. Prophylactic pancreatic stentplacement and post-ERCP pancreatitis:an updated Meta-analysis[J].J Gastroenterol, 2014, 49(2):343-355.
[59]Afghani E, Akshintala VS, Khashab MA, et al. 5-Fr vs. 3-Fr pancreaticstentsforthepreventionofpost-ERCPpancreatitisinhigh-risk patients:a systematic review and network Meta-analysis[J].Endoscopy, 2014, 46(7):573-580.
[60]Zolotarevsky E, Fehmi SM, Anderson MA, et al. Prophylactic 5-Frpancreaticductstentsaresuperiorto3-Frstents:arandomizedcontrolled trial[J]. Endoscopy, 2011, 43(4):325-330.
[61]Pahk A, Rigaux J, Poreddy V, et al. Prophylactic pancreatic stents:does size matter? A comparison of 4-Fr and 5-Fr stents in referenceto post-ERCP pancreatitis and migration rate[J]. Dig Dis Sci, 2011,56(10):3058-2064.
[62]ChoksiNS,FogelEL,CoteGA,etal.Theriskofpost-ERCPpancreatitisandtheprotectiveeffectofrectalindometh acinincases of attempted but unsuccessful prophylactic pancreatic stentplacement[J]. Gastrointest Endosc, 2015, 81(1):150-155.
[63]ArainMA,FreemanML.Pancreaticstentplacementremainsacornerstone of prevention of post-ERCP pancreatitis, but it requiresspecialized techniques[J]. Gastrointest Endosc, 2015, 81(1):156-158.
[64]WangP,LiZS,LiuF,etal.RiskfactorsforERCP-relatedcomplications:aprospectivemulticenterstudy[J].A mJGastroenterol, 2009, 104(1):31-40.
[65]HalttunenJ,MeisnerS,AabakkenL,etal.Difficultcannulationas defined by a prospective study of the Scandinavian AssociationforDigestiveEndoscopy(SADE)in907ERCPs[J].ScandJGastroenterol, 2014, 49(6):752-758.
[66]Tse F, Yuan Y, Bukhari M, et al. Pancreatic duct guidewire placementforbiliarycannulationforthepreventionofpost-endoscopicretrogradecholangiopancreatography(ERCP)pancreatitis[J].Cochrane Database Syst Rev, 2016, 5(1):CD010571.
[67]Tse F, Yuan Y, Moayyedi P, et al. Guide wire-assisted cannulation forthe prevention of post-ERCP pancreatitis:a systematic review andMeta-analysis[J]. Endoscopy, 2013, 45(8):605-618.
[68]Gong B, Hao L, Bie L, et al. Does precut technique improve selectivebile duct cannulation or increase post-ERCP pancreatitis rate? AMeta-analysis of randomized controlled trials[J]. Surg Endosc, 2010,24(11):2670-2680.
[69]Lopes L, Dinisribeiro M, Rolanda C. Safety and efficacy of precutneedle-knife fistulotomy[J]. Scand J Gastroenterol, 2014, 49(6):759-765.
[70]Liu Y, Su P, Lin S, et al. Endoscopic papillary balloon dilatation versusendoscopic sphincterotomy in the treatment for choledocholith iasis:A Meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(3):464-471.
[71]Liao W, Tu Y, Wu M, et al. Balloon dilation with adequate durationissaferth ansphincterotomyforextractingbileductstones:asystematic review and Meta-analyses[J]. Clin Gastroenterol Hepatol,2012, 10(10):1101-1109.
[72]Liao WC, Lee CT, Chang CY, et al. Randomized trial of 1-minuteversus 5-minute endoscopic balloon dilation for extraction of bileduct stones[J]. Gastrointest Endosc, 2010, 72(6):1154-1162.
[73]YangXM,HuB.Endoscopicsphincterotomypluslarge-balloondilation vs endoscopic sphincterotomy for choledocholith iasis:aMeta-analysis[J]. World J Gastroenterol, 2013, 19(48):9453-9460.
[2]Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomycomplications and their management:an attempt at consensus[J].Gastrointest Endosc, 1991, 37(3):383-393.
[3]BanksPA,BollenTL,DervenisC,etal.Classificationofacutepancreatitis—2012:revisionoftheAtlantaclassificationanddefinitions by international consensus[J]. Gut, 2013, 62(1):102-111.
[4]Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications:A systematic survey of prospective studies[J].Am J Gastroenterol, 2007, 102(8):1781-1788.
[5]Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, andmortality of post-ERCP pancreatitis:a systematic review by usingrandomized, controlled trials[J]. Gastrointest Endosc, 2015, 81(1):143-149.
[6]Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis:European Society of Gastrointestinal Endoscopy(ESGE)Guideline-updated June 2014[J]. Endoscopy, 2014, 46(9):799-815.
[7]ChenJJ,WangXM,LiuXQ,etal.Riskfactorsforpost-ERCPpancreatitis:a systematic review of clinical trials with a large samplesize in the past 10 years[J]. Eur J Med Res, 2014, 19(1):26.
[8]Inamdar S, Berzin TM, Sejpal DV, et al. Pregnancy is a risk factor forpancreatitis after endoscopic retrograde cholangiopancreatography ina national cohort study[J]. Clin Gastroenterol Hepatol, 2016, 14(1):107-114.
[9]Koksal AR, Boga S, Alkim H, et al. Insulin resistance as a novel riskfactor for post-ERCP pancreatitis:A pilot study[J]. Dig Dis Sci,2016, 61(8):2397-2405.
[10]Dumonceau JM, Rigaux J, Kahaleh M, et al. Prophylaxis of post-ERCP pancreatitis:a practice survey[J]. Gastrointest Endosc, 2010,71(6):934-939.
[11]Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial ofrectal indometh acin to prevent post-ERCP pancreatitis[J]. N Engl JMed, 2012, 366(15):1414-1422.
[12]A h m a dD,L o p e zK T,E s m a d iM A,e ta l.T h ee f f e c to findometh acininthepreventionofpost-endoscopicretrogradecholangiopancreatography pancreatitis:a Meta-analysis[J]. Pancreas,2014, 43(3):338-342.
[13]AkbarA,AbuDayyehBK,BaronTH,etal.Rectalnonsteroidalant i-inf lammator ydr ugsaresu per iortopancreat icductstentsinpreventingpancreatitisafterendoscopicretrogradecholangiopancreatography:anetworkMeta-analysis[J].ClinGastroenterol Hepatol, 2013, 11(7):778-783.
[14]LuoH,ZhaoL,LeungJ,etal.Routinepre-proceduralrectalindometacin versus selective post-procedural rectal indometacin toprevent pancreatitis in patients undergoing endoscopic retrogradecholangiopancreatography:a multicentre, single-blinded, randomisedcontrolled trial[J]. Lancet, 2016, 387(10035):2293-2301.
[15]Dumonceau JM, Andriulli A, Devière J, et al. European Society ofGastrointestinal Endoscopy(ESGE)Guideline:prophylaxis of post-ERCP pancreatitis[J]. Endoscopy, 2010, 42(6):503-515.
[16]Concepción-Martín M, Gómez-Oliva C, Juanes A, et al. Somatostatinfor prevention of post-ERCP pancreatitis:a randomized, double-blind trial[J]. Endoscopy, 2014, 46(10):851-856.
[17]Bai Y, Ren X, Zhang XF, et al. Prophylactic somatostatin can reduceincidenceofpost-ERCPpancreatitis:multicenterrandomizedcontrolled trial[J]. Endoscopy, 2015, 47(5):415-420.
[18]Bai Y,Gao J,Zou DW,et al.Prophylacticoctreotid eadministrationdoesnotpreventpost-endoscopicretrogradecholangiopancreatographypancreatitis:aMeta-analysisofrandomized controlled trials[J]. Pancreas, 2008, 37(3):241-246.
[19]Zhang Y, Chen QB, Gao ZY, et al. Meta-analysis:octreotide preventspost-ERCP pancreatitis, but only at sufficient doses[J]. AlimentPharmacol Ther, 2009, 29(11):1155-1164.
[20]Omata F, Deshpande G, Tokuda Y, et al. Meta-analysis:somatostatinor its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis[J]. J Gastroenterol, 2010, 45(8):885-895.
[21]Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatinandgabexatemesylateforthepreventionofpost-endoscopicretrograde cholangiopancreatography pancreatitis:a prospective,randomized trial[J]. J Gastroenterol, 2007, 42(2):161-167.
[22]Fuji shiroH,AdachiKT,HashimotoT,etal.U l inastatins how spreventiveeffectonpost-endoscopicretrograd echolangiopancreatography pancreatitis in a multicenter prospectiverandomized study[J]. J Gastroenterol Hepatol, 2006, 21(6):1065-1069.
[23]YooYW,ChaSW,KimA,etal.Theuseofgabexatemesylateand ulinastatin for the prevention of post-endoscopic retrogradecholangiopancreatography pancreatitis[J]. Gut Liver, 2012, 6(2):256-261.
[24]Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis ofpost-ERCP pancreatitis:a Meta-analysis of randomized controlledtrials[J]. BMC Gastroenterol, 2007, 7(1):6.
[25]Seta T, Noguchi Y. Protease inhibitors for preventing complicationsassociated with ERCP:an updated Meta-analysis[J]. GastrointestEndosc, 2011, 73(4):700-706.
[26]BaiY,XuC,YangX,etal.Glyceryltrinitrateforpreventionofpancreatitis after endoscopic retrograde cholangiopancreatography:a Meta-analysis of randomized, double-blind, placebo-controlledtrials[J]. Endoscopy, 2009, 41(8):690-695.
[27]Shao LM, Chen QY, Chen MY, et al. Nitroglycerin in the preventionof post-ERCP pancreatitis:a Meta-analysis[J]. Dig Dis Sci, 2010,55(1):1-7.
[28]Chen B, Fan T, Wang C. A Meta-analysis for the e?ect of prophylacticGTNontheincidenceofpost-ERCPpancreatitisandonthesuccessful rate of cannulation of bile ducts[J]. BMC gastroenterol,2010, 10(1):85.
[29]Ding J, Jin X, Pan Y, et al. Glyceryl trinitrate for prevention of post-ERCP pancreatitis and improve the rate of cannulation:a Meta-analysis of prospective, randomized, controlled trials[J]. PLoS One,2013, 8(10):e75645.
[30]BangUC,N?jgaardC,AndersenPK,etal.Meta-analysis:Nitroglycerin for prevention of post-ERCP pancreatitis[J]. AlimentPharmacol Ther, 2009, 29(10):1078-1085.
[31]Matsushita M, Takakuwa H, Shimeno N, et al. Epinephrine sprayedonthepapillaforpreventionofpost-ERCPpancreatitis[J].JGastroenterol, 2009, 44(1):71-75.
[32]XuLH,QianJB,GuLG,etal.Preventionofpost-endoscopicretrograde cholangiopancreatography pancreatitis by epinephrinesprayed on the papilla[J]. J Gastroenterol Hepatol, 2011, 26(7):1139-1144.
[33]Sand J, Matikainen M, Nordback I. Antibiotic prophylaxis reducespost-ERCPpancreatitis[J].Gastroenterology,2000,118(4):A1062-A1062.
[34]R?ty S, Sand J, Pulkkinen M, et al. Post-ERCP pancreatitis:reductionby routine antibiotics[J]. J Gastrointest Surg, 2001, 5(4):339-345.
[35]Buxbaum J, Yan A, Yeh K, et al. Aggressive hydration with lactatedRinger’ssolutionreducespancreatitisfollowingendoscopicretrogradecholangiopancreatography[J].ClinGastroenterolHepatol, 2014, 12(2):303-307.
[36]Dimagno MJ, Wamsteker EJ, Maratt J, et al. Do larger periproceduralfluid volumes reduce the severity of post-endoscopic retrogradecholangiopancreatography pancreatitis?[J]. Pancreas, 2014, 43(4):642-647.
[37]Choi JH, Kim HJ, Lee BU, et al. Vigorous periprocedural hydrationwith lactated Ringer solution reduces the risk of pancreatitis afterretrograde cholangiopancreatography in hospitalized patients[J].Clin Gastroenterol Hepatol, 2017, 15(1):86-92.
[38]SmeetsX J,DaCD,BesselinkMG,etal.Systematicreview:periproceduralhydrationinthepreventionofpost-ERCPpancreatitis[J]. Aliment Pharmacol Ther, 2016, 44(6):541-553.
[39]ZhangZF,DuanZJ,WangLX,etal.Aggressivehydrationwith lactated Ringer solution in prevention of postendoscopic retrogradecholangiopancreatographypancreatitis:AMeta-analysisofrandomized controlled trials[J]. J Clin Gastroenterol, 2017, 51(3):e17-e26.
[40]Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotideversushydrocortisoneversusplacebointhepreventionofpost-ERCP pancreatitis:a multicenter randomized controlled trial[J].Gastrointest Endosc, 2002, 55(4):470-475.
[41]Bai Y, Gao J, Shi X, et al. Prophylactic corticosteroids do not preventpost-ERCP pancreatitis:a Meta-analysis of randomized controlledtrials[J]. Pancreatology, 2008, 8(4/5):504-509.
[42]Schwartz JJ, Lew RJ, Ahmad NA. The effect of lidocaine sprayedonthemajorduodenalpapillaonthefrequencyofpost-ERCPpancreatitis[J]. Gastrointest Endosc, 2004, 59(2):179-184.
[43]Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis:a prospective, double-blind randomized study[J].Gastrointest Endosc, 2002, 56(2):202-208.
[44]GuWJ,WeiCY,YinRX.Antioxidantsupplementationfortheprevention of post-endoscopic retrograde cholangiopancreatographypancreatitis:a Meta-analysis of randomized controlled trials[J]. NutrJ, 2013, 12(1):23.
[45]BarkayO,NivEE,BruckR,etal.Low-doseheparinforthepreventionofpost-ERCPpancreatitis:arandomizedplacebo-controlled trial[J]. Surg Endosc, 2008, 22(9):1971-1976.
[46]Sherman S, Cheng CL, Costamagna G, et al. E?cacy of recombinanth uman interleukin-10 in prevention of post-endoscopic retrogradecholangiopancreatography pancreatitis in subjects with increasedrisk[J]. Pancreas, 2009, 38(3):267-274.
[47]Dumot JA, Conwell DL, Jr ZG, et al. A randomized, double blindstudyofinterleukin10forthepreventionofERCP-inducedpancreatitis[J]. Am J Gastroenterol, 2001, 96(7):2098-2102.
[48]van Westerloo DJ, Rauws EA, Hommes D, et al. Pre-ERCP infusionof semapimod, a mitogen-activated protein kinases inhibitor, lowerspost-ERCPhyperamylasemiabutnotpancreatitisincidence[J].Gastrointest Endosc, 2008, 68(2):246-254.
[49]BaiY,GaoJ,ZhangW,etal.Meta‐analysis:allopurinolintheprevention of postendoscopic retrograde cholangiopancreatographypancreatitis[J]. Aliment Pharmacol Ther, 2008, 28(5):557-564.
[50]Li S, Cao G, Chen X, et al. Low-dose heparin in the prevention ofpost endoscopic retrograde cholangiopancreatography pancreatitis:asystematic review and Meta-analysis[J]. Eur J Gastroenterol Hepatol,2012, 24(5):477-481.
[51]KatsinelosP,KountourasJ,ParoutoglouG,etal.IntravenousN-acetylcysteinedoesnotpreventpost-ERCPpancreatitis[J].Gastrointest Endosc, 2005, 62(1):105-111.
[52]SatoD,ShibaharaT,MiyazakiK,etal.Efficacyofendoscopicnasobiliary drainage for the prevention of pancreatitis after papillaryballoon dilatation:a pilot study[J]. Pancreas, 2005, 31(1):93-97.
[53]SongLY,ZhaoQX,KongXJ,etal.EfficacyofENBDinthepreventionofpost-ERCPpancreatitisandhyperamylasemiainpatients with common bile duct stones:an analysis of 65 cases[J].World Chin J Digestol, 2010, 18(16):1724-1727.
[54]ChoudharyA,BechtoldML,ArifM,etal.Pancreaticstentsforprophylaxis against post-ERCP pancreatitis:a Meta-analysis andsystematic review[J]. Gastrointest Endosc, 2011, 73(2):275-282.
[55]ChaSW,LeungWD,LehmanGA,etal.Doesleavingamainpancreatic duct stent in place reduce the incidence of precut biliarysphincterotomy-associated pancreatitis? A randomized, prospectivestudy[J]. Gastrointest Endosc, 2013, 77(2):209-216.
[56]Arain MA, Freeman ML. Pharmacologic prophylaxis alone is notadequate to prevent post-ERCP pancreatitis[J]. Am J Gastroenterol,2014, 109(6):910-912.
[57]Ananya D, Pankaj S, Sivak MV, et al. Pancreatic-stent placementforpreventionofpost-ERCPpancreatitis:Acost-effectivenessanalysis[J]. Gastrointest Endosc, 2007, 65(7):960-968.
[58]Mazaki T, Mado K, Masuda H, et al. Prophylactic pancreatic stentplacement and post-ERCP pancreatitis:an updated Meta-analysis[J].J Gastroenterol, 2014, 49(2):343-355.
[59]Afghani E, Akshintala VS, Khashab MA, et al. 5-Fr vs. 3-Fr pancreaticstentsforthepreventionofpost-ERCPpancreatitisinhigh-risk patients:a systematic review and network Meta-analysis[J].Endoscopy, 2014, 46(7):573-580.
[60]Zolotarevsky E, Fehmi SM, Anderson MA, et al. Prophylactic 5-Frpancreaticductstentsaresuperiorto3-Frstents:arandomizedcontrolled trial[J]. Endoscopy, 2011, 43(4):325-330.
[61]Pahk A, Rigaux J, Poreddy V, et al. Prophylactic pancreatic stents:does size matter? A comparison of 4-Fr and 5-Fr stents in referenceto post-ERCP pancreatitis and migration rate[J]. Dig Dis Sci, 2011,56(10):3058-2064.
[62]ChoksiNS,FogelEL,CoteGA,etal.Theriskofpost-ERCPpancreatitisandtheprotectiveeffectofrectalindometh acinincases of attempted but unsuccessful prophylactic pancreatic stentplacement[J]. Gastrointest Endosc, 2015, 81(1):150-155.
[63]ArainMA,FreemanML.Pancreaticstentplacementremainsacornerstone of prevention of post-ERCP pancreatitis, but it requiresspecialized techniques[J]. Gastrointest Endosc, 2015, 81(1):156-158.
[64]WangP,LiZS,LiuF,etal.RiskfactorsforERCP-relatedcomplications:aprospectivemulticenterstudy[J].A mJGastroenterol, 2009, 104(1):31-40.
[65]HalttunenJ,MeisnerS,AabakkenL,etal.Difficultcannulationas defined by a prospective study of the Scandinavian AssociationforDigestiveEndoscopy(SADE)in907ERCPs[J].ScandJGastroenterol, 2014, 49(6):752-758.
[66]Tse F, Yuan Y, Bukhari M, et al. Pancreatic duct guidewire placementforbiliarycannulationforthepreventionofpost-endoscopicretrogradecholangiopancreatography(ERCP)pancreatitis[J].Cochrane Database Syst Rev, 2016, 5(1):CD010571.
[67]Tse F, Yuan Y, Moayyedi P, et al. Guide wire-assisted cannulation forthe prevention of post-ERCP pancreatitis:a systematic review andMeta-analysis[J]. Endoscopy, 2013, 45(8):605-618.
[68]Gong B, Hao L, Bie L, et al. Does precut technique improve selectivebile duct cannulation or increase post-ERCP pancreatitis rate? AMeta-analysis of randomized controlled trials[J]. Surg Endosc, 2010,24(11):2670-2680.
[69]Lopes L, Dinisribeiro M, Rolanda C. Safety and efficacy of precutneedle-knife fistulotomy[J]. Scand J Gastroenterol, 2014, 49(6):759-765.
[70]Liu Y, Su P, Lin S, et al. Endoscopic papillary balloon dilatation versusendoscopic sphincterotomy in the treatment for choledocholith iasis:A Meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(3):464-471.
[71]Liao W, Tu Y, Wu M, et al. Balloon dilation with adequate durationissaferth ansphincterotomyforextractingbileductstones:asystematic review and Meta-analyses[J]. Clin Gastroenterol Hepatol,2012, 10(10):1101-1109.
[72]Liao WC, Lee CT, Chang CY, et al. Randomized trial of 1-minuteversus 5-minute endoscopic balloon dilation for extraction of bileduct stones[J]. Gastrointest Endosc, 2010, 72(6):1154-1162.
[73]YangXM,HuB.Endoscopicsphincterotomypluslarge-balloondilation vs endoscopic sphincterotomy for choledocholith iasis:aMeta-analysis[J]. World J Gastroenterol, 2013, 19(48):9453-9460.